Identifying and meeting the challenges of insulin therapy in type 2 diabetes

References

• HellerSKozlovskiPKurtzhalsPInsulin’s 85th anniversary – An enduring medical miracleDiabetes Res Clin Pract200778214915817482306
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVHolmanRRGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) GroupJAMA1999281212005201210359389
   PubMed Web of Science ®Google Scholar
• UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study GroupDiabetes Care199821187929538975
   PubMed Web of Science ®Google Scholar
• WengJLiYXuWEffect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trialLancet200837196261753176018502299
   PubMed Web of Science ®Google Scholar
• Le FlochJPCritical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabeticsDiabetes Metab Syndr Obes2010319721321437089
   PubMedGoogle Scholar
• DaileyGNew strategies for basal insulin treatment in type 2 diabetes mellitusClin Ther200426688990115262459
   PubMed Web of Science ®Google Scholar
• GarveyWTOlefskyJMGriffinJHammanRFKoltermanOGThe effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitusDiabetes19853432222343882489
   PubMed Web of Science ®Google Scholar
• RobertsonRPOlsonLKZhangHJDifferentiating glucose toxicity from glucose desensitization: a new message from the insulin geneDiabetes1994439108510898070607
   PubMed Web of Science ®Google Scholar
• WrightABurdenACPaiseyRBCullCAHolmanRRUK Prospective Diabetes Study GroupSulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)Diabetes Care200225233033611815505
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROAmerican Diabetes AssociationAmerican College of Cardiology FoundationAmerican Heart AssociationIntensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart AssociationJ Am Coll Cardiol200953329830419147051
   PubMed Web of Science ®Google Scholar
• GersteinHCBoschJDagenaisGRORIGIN Trial InvestigatorsBasal insulin and cardiovascular and other outcomes in dysglycemiaN Engl J Med2012367431932822686416
   PubMed Web of Science ®Google Scholar
• MellbinLGRydénLRiddleMCORIGIN Trial InvestigatorsDoes hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trialEur Heart J201334403137314423999452
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S14S8024357209
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFMoghissiETiktinMHirschIBInzucchiSEGenuthSIndividualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trialsAnn Intern Med2011154855455921502652
   PubMed Web of Science ®Google Scholar
• CheungBMOngKLChernySSShamPCTsoAWLamKSDiabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006Am J Med2009122544345319375554
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar
• SimonsonGDCuddihyRMReaderDBergenstalRMInternational Diabetes Center Treatment of Type 2 Diabetes Glucose AlgorithmDiabetes Management201112175189
   Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• SpannSJNuttingPAGalliherJMManagement of type 2 diabetes in the primary care setting: a practice-based research network studyAnn Fam Med200641233116449393
   PubMed Web of Science ®Google Scholar
• KarterAJSubramanianUSahaCBarriers to insulin initiation: the translating research into action for diabetes insulin starts projectDiabetes Care201033473373520086256
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRKrugerDFTravisLBCorrelates of insulin injection omissionDiabetes Care201033224024520103556
   PubMed Web of Science ®Google Scholar
• PhillipsLSBranchWTCookCBClinical inertiaAnn Intern Med2001135982583411694107
   PubMed Web of Science ®Google Scholar
• el-KebbiIMZiemerDCGallinaDLDunbarVPhillipsLSDiabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocolsDiabetes Care199922101617162010526724
   PubMed Web of Science ®Google Scholar
• BrownJBNicholsGAPerryAThe burden of treatment failure in type 2 diabetesDiabetes Care20042771535154015220224
   PubMed Web of Science ®Google Scholar
• CuddihyRMPhilis-TsimikasANazeriAType 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY surveyDiabetes Educ201137111112321131599
   PubMed Web of Science ®Google Scholar
• HayesRPFitzgeraldJTJacoberSJPrimary care physician beliefs about insulin initiation in patients with type 2 diabetesInt J Clin Pract200862686086818393965
   PubMed Web of Science ®Google Scholar
• LaSalleJREmpowering patients during insulin initiation: a real-world approachJ Am Osteopath Assoc20101102697820160245
   PubMedGoogle Scholar
• BruntonSGoughSHicksDA look into the future: improving diabetes care by 2015Curr Med Res Opin201127Suppl 3657221781013
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2013Diabetes Care201336Suppl 1S11S6623264422
   PubMed Web of Science ®Google Scholar
• BenroubiMFear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetesDiabetes Res Clin Pract201193Suppl 1S97S9921864760
   PubMed Web of Science ®Google Scholar
• CryerPEHypoglycemia in Diabetes: Pathophysiology, Prevalence, and PreventionAlexandria, VAAmerican Diabetes Association2009
   Google Scholar
• Workgroup on Hypoglycemia, American Diabetes AssociationDefining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on HypoglycemiaDiabetes Care20052851245124915855602
   PubMed Web of Science ®Google Scholar
• BrodMChristensenTThomsenTLBushnellDMThe impact of non-severe hypoglycemic events on work productivity and diabetes managementValue Health201114566567121839404
   PubMed Web of Science ®Google Scholar
• MillerCDPhillipsLSZiemerDCGallinaDLCookCBEl-KebbiIMHypoglycemia in patients with type 2 diabetes mellitusArch Intern Med2001161131653165911434798
   PubMedGoogle Scholar
• VexiauPMavrosPKrishnarajahGLyuRYinDHypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in FranceDiabetes Obes Metab200810Suppl 1162418435670
   PubMed Web of Science ®Google Scholar
• PrammingSThorsteinssonBBendtsonIBinderCSymptomatic hypoglycaemia in 411 type 1 diabetic patientsDiabet Med1991832172221828735
   PubMed Web of Science ®Google Scholar
• UngerJParkinCHypoglycemia in insulin-treated diabetes: a case for increased vigilancePostgrad Med20111234819121680992
   PubMed Web of Science ®Google Scholar
• BruntonSANocturnal hypoglycemia: answering the challenge with long-acting insulin analogsMedGenMed2007923817955093
   PubMedGoogle Scholar
• AllenKVFrierBMNocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward preventionEndocr Pract20039653054314715482
   PubMedGoogle Scholar
• RiddleMCRosenstockJGerichJInsulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care200326113080308614578243
   PubMed Web of Science ®Google Scholar
• RosenstockJDaileyGMassi-BenedettiMFritscheALinZSalzmanAReduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesDiabetes Care200528495095515793205
   PubMed Web of Science ®Google Scholar
• RosenstockJSchwartzSLClarkCMParkGDDonleyDWEdwardsMBBasal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulinDiabetes Care200124463163611315821
   PubMed Web of Science ®Google Scholar
• HaakTTiengoADraegerESuntumMWaldhäuslWLower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes Obes Metab200571566415642076
   PubMed Web of Science ®Google Scholar
• LittleSShawJHomePHypoglycemia rates with basal insulin analogsDiabetes Technol Ther201113Suppl 1S53S6421668338
   PubMed Web of Science ®Google Scholar
• LevinPAMerseyJHZhouSBrombergerLAClinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitusEndocr Pract2012181172521742605
   PubMed Web of Science ®Google Scholar
• SchappertSMRechtsteinerEAAmbulatory medical care utilization estimates for 2007Vital Health Stat2011169138
   Google Scholar
• GreavesCJBrownPTerryRTEiserCLingsPSteadJWConverting to insulin in primary care: an exploration of the needs of practice nursesJ Adv Nurs200342548749612752869
   PubMed Web of Science ®Google Scholar
• FridAHirschLGasparRScientific Advisory Board for the Third Injection Technique WorkshopNew injection recommendations for patients with diabetesDiabetes Metab201036Suppl 1S3S1820933208
   PubMed Web of Science ®Google Scholar
• NakarSYitzhakiGRosenbergRVinkerSTransition to insulin in Type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriersJ Diabetes Complications200721422022617616351
   PubMed Web of Science ®Google Scholar
• PolonskyWHFisherLGuzmanSVilla-CaballeroLEdelmanSVPsychological insulin resistance in patients with type 2 diabetes: the scope of the problemDiabetes Care200528102543254516186296
   PubMed Web of Science ®Google Scholar
• MeeceJDispelling myths and removing barriers about insulin in type 2 diabetesDiabetes Educ200632Suppl 19S18S16439485
   PubMed Web of Science ®Google Scholar
• DonnanPTMacDonaldTMMorrisADAdherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort studyDiabet Med200219427928411942998
   PubMed Web of Science ®Google Scholar
• PeyrotMBarnettAHMeneghiniLFSchumm-DraegerPMInsulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabet Med201229568268922313123
   PubMed Web of Science ®Google Scholar
• RatnerRWynneANakhleSBruscoOVlajnicARendellMInfluence of preprandial vs postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096)Diabetes Obes Metab201113121142114821812890
   PubMed Web of Science ®Google Scholar
• MeneghiniLMersebachHKumarSSvendsenALHermansenKComparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized studyEndocr Pract201117572773621550957
   PubMed Web of Science ®Google Scholar
• RaccahDHaakTHuetDStepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus [abstract]Diabetologia201053Suppl 1S382
   Google Scholar
• HirschIBInsulin analoguesN Engl J Med2005352217418315647580
   PubMed Web of Science ®Google Scholar
• Vázquez-CarreraMSilvestreJSInsulin analogues in the management of diabetesMethods Find Exp Clin Pharmacol200426644546115349139
   PubMedGoogle Scholar
• UlrichHSnyderBGargSKCombining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisineVasc Health Risk Manag20073324525417703632
   PubMedGoogle Scholar
• HomePDLindholmAHyllebergBRoundPImproved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study GroupDiabetes Care19982111190419099802741
   PubMed Web of Science ®Google Scholar
• AndersonJHJrBrunelleRLKoivistoVATrautmannMEVignatiLDiMarchiRImproved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study GroupClin Ther199719162729083709
   PubMed Web of Science ®Google Scholar
• HartmanIInsulin analogs: impact on treatment success, satisfaction, quality of life, and adherenceClin Med Res200862546718801953
   PubMedGoogle Scholar
• HeinemannLLinkeschovaRRaveKHompeschBSedlakMHeiseTTime-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placeboDiabetes Care200023564464910834424
   PubMed Web of Science ®Google Scholar
• SuzukiDToyodaMKondoMEfficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetesTokai J Exp Clin Med2012372354022763825
   PubMedGoogle Scholar
• RaskinPGylvinTWengWChaykinLComparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetesDiabetes Metab Res Rev200925654254819565569
   PubMed Web of Science ®Google Scholar
• PlankJBodenlenzMSinnerFA double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemirDiabetes Care20052851107111215855574
   PubMed Web of Science ®Google Scholar
• KleinOLyngeJEndahlLDamholtBNosekLHeiseTAlbumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab20079329029917391154
   PubMed Web of Science ®Google Scholar
• LeporeMPampanelliSFanelliCPharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lisproDiabetes200049122142214811118018
   PubMed Web of Science ®Google Scholar
• MeneghiniLAtkinSLBainSFlexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetesDiabetes201160Suppl 1LB10LB11
   Google Scholar
• Russell-JonesDLHollanderPMiranda-PalmaBAltering the time of day of once-daily dosing of insulin degludec achieves similar glycemic control and safety compared to dosing the same time of day in people with type 1 diabetesDiabetes201261Suppl 1A91
   Google Scholar
• MathieuCHollanderPMiranda-PalmaBInsulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycemic control with less nocturnal hypoglycemia than insulin glargine over 52 weeksCan J Diabetes2012365S56S57
   Google Scholar
• HirschLGibneyMBerubeJManocchioJImpact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetesJ Diabetes Sci Technol20126232833522538142
   PubMedGoogle Scholar
• KorytkowskiMBellDJacobsenCSuwannasariRFlexPen Study TeamA multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitusClin Ther200325112836284814693308
   PubMed Web of Science ®Google Scholar
• FloodTAdvances in insulin delivery systems and devices: beyond the vial and syringeInsulin20061399108
   Google Scholar
• CobbleMEInitiating and intensifying insulin therapy for type 2 diabetes: why, when, and howAm J Ther2009161566419142156
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRLauritzenTInternational DAWN Advisory PanelResistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) studyDiabetes Care200528112673267916249538
   PubMed Web of Science ®Google Scholar
• PolonskyWHHajosTRDainMPSnoekFJAre patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international populationCurr Med Res Opin20112761169117421469914
   PubMed Web of Science ®Google Scholar
• MarreroDGOvercoming patient barriers to initiating insulin therapy in type 2 diabetes mellitusClin Cornerstone2007823340 discussion 41–4318357954
   PubMedGoogle Scholar
• CameronCGBennettHACost-effectiveness of insulin analogues for diabetes mellitusCMAJ2009180440040719221353
   PubMed Web of Science ®Google Scholar
• TunisSLMinshallMEConnerCCost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysisCurr Med Res Opin20092551273128419366302
   PubMed Web of Science ®Google Scholar
• TunisSLSauriolLMinshallMECost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in CanadaAppl Health Econ Health Policy20108426728020578781
   PubMedGoogle Scholar
• BullanoMFAl-ZakwaniISFisherMDMendittoLWilleyVJDifferences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin productsCurr Med Res Opin200521229129815802000
   PubMed Web of Science ®Google Scholar
• BorahBJDarkowTBouchardJAagrenMFormaFAlemayehuBA comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetesClin Ther200931362363119393853
   PubMed Web of Science ®Google Scholar
• CharbonnelBPenfornisAVarroud-VialMKusnik-JoinvilleODetournayBInsulin therapy for diabetes mellitus: treatment regimens and associated costsDiabetes Metab201238215616322172400
   PubMed Web of Science ®Google Scholar
• GuQZengFPatelBVTripoliLCPart D coverage gap and adherence to diabetes medicationsAm J Manag Care2010161291191821348561
   PubMed Web of Science ®Google Scholar
• BonafedeMMKalsekarAPawaskarMInsulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysisBMC Endocr Disord201111321226935
   PubMed Web of Science ®Google Scholar
• LeeWCBaluSCobdenDJoshiAVPashosCLCopayment level and medication adherence in type 2 diabetes patients managed with insulin aspart pen therapy [abstract]Value Health200710A63
   Web of Science ®Google Scholar
• AydinCMTaylorRBillingtonEOTildesleyHDInsulin therapy is no cheaper than thiazolidinedione therapy in patients with type 2 diabetesBC Med J2006488392398
   Google Scholar
• MeneghiniLAdvances in insulin therapy: physiological replacement with insulin analogsUS Endocrinol200712728
   Google Scholar
• SøndergaardLGStoltenbergMFlyvbjergAZinc ions in beta-cells of obese, insulin-resistant, and type 2 diabetic rats traced by autometallographyAPMIS2003111121147115414678025
   PubMed Web of Science ®Google Scholar
• DaileyGRosenstockJMosesRGWaysKInsulin glulisine provides improved glycemic control in patients with type 2 diabetesDiabetes Care200427102363236815451901
   PubMed Web of Science ®Google Scholar
• PalaLMannucciEDicembriniIRotellaCMA comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patientsDiabetes Res Clin Pract200778113213517445933
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLRønnBBLower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesDiabetes20045361614162015161770
   PubMed Web of Science ®Google Scholar
• MeneghiniLFOrozco-BeltranDKhuntiKWeight beneficial treatments for type 2 diabetesJ Clin Endocrinol Metab201196113337335321900381
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHDresslerAZiemenMHOE 901/300s Study GroupLess nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study GroupDiabetes Care20002381130113610937510
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDerezinskiTMartinez RavnGClausonPHomePA 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetes Care20062961269127416732007
   PubMed Web of Science ®Google Scholar
• HeiseTTackCJCuddihyRA new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialDiabetes Care201134366967421285389
   PubMed Web of Science ®Google Scholar
• HeiseTPieberTRTowards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes Obes Metab20079564865917645556
   PubMed Web of Science ®Google Scholar
• ShanikMHIntensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetesDiabetes Technol Ther201214653353922364142
   PubMed Web of Science ®Google Scholar
• BoehmBOHomePDBehrendCKampNMLindholmAPremixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patientsDiabet Med200219539339912027927
   PubMed Web of Science ®Google Scholar
• GarberAJPremixed insulin analogues for the treatment of diabetes mellitusDrugs2006661314916398567
   PubMed Web of Science ®Google Scholar
• RoachPYueLAroraVImproved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study GroupDiabetes Care19992281258126110480767
   PubMed Web of Science ®Google Scholar
• TibaldiJTBiphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practiceAdv Ther20072461348135618165218
   PubMed Web of Science ®Google Scholar
• KiloCMezitisNJainRMerseyJMcGillJRaskinPStarting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metforminJ Diabetes Complications200317630731314583174
   PubMed Web of Science ®Google Scholar
• ArnoldsSKuglinBKapitzaCHeiseTHow pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetesInt J Clin Pract201064101415142420618882
   PubMed Web of Science ®Google Scholar
• JonassenIHavelundSRibelUInsulin degludec: multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulinDiabetologia201053Suppl 1S388
   Google Scholar
• KurtzhalsPHeiseTStraussHMMulti-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec [abstract]Diabetes201160Suppl 1ALB12
   Google Scholar
• GarberAJKingABDel PratoSNN1250-3582 (BEGIN BB T2D) Trial InvestigatorsInsulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trialLancet201237998251498150722521072
   PubMed Web of Science ®Google Scholar
• NiskanenLLeiterLAFranekEComparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trialEur J Endocrinol2012167228729422660026
   PubMed Web of Science ®Google Scholar
• KrasnerAPohlRSimmsPPichottaPHauserRDe SouzaEA review of a family of ultra-rapid-acting insulins: formulation developmentJ Diabetes Sci Technol20126478679622920803
   PubMedGoogle Scholar
• PohlRHauserRLiMUltra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge maskingJ Diabetes Sci Technol20126475576322920799
   PubMedGoogle Scholar
• CastleJRMorrowLPittsAEvaluations of modified ultra-rapid acting Linjeta™ formulations BIOD-105 and BIOD-107 in patients with type 1 diabetes [abstract]Diabetes201261Suppl 1A91
   Google Scholar
• BergenstalRMRosenstockJArakakiRFA randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetesDiabetes Care201235112140214722787177
   PubMed Web of Science ®Google Scholar
• AndersonBJRedondoMJWhat can we learn from patient-reported outcomes of insulin pen devices?J Diabetes Sci Technol2011561563157122226279
   PubMedGoogle Scholar
• GoldsteinHHPen devices to improve patient adherence with insulin therapy in type 2 diabetesPostgrad Med2008120317217918824835
   PubMed Web of Science ®Google Scholar
• CobdenDLeeWCBaluSJoshiAVPashosCLHealth outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitusPharmacotherapy200727794896217594200
   PubMed Web of Science ®Google Scholar
• LeeWCBaluSCobdenDJoshiAVPashosCLMedication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims dataClin Ther2006281017121725 discussion 1710–171117157128
   PubMed Web of Science ®Google Scholar
• BaserOBouchardJDeLuzioTHenkHAagrenMAssessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringeAdv Ther20102729410420352392
   PubMed Web of Science ®Google Scholar
• BodeBWInsulin pump use in type 2 diabetesDiabetes Technol Ther201012Suppl 1S17S2120515301
   PubMed Web of Science ®Google Scholar
• WhiteRDInsulin pump therapy (continuous subcutaneous insulin infusion)Prim Care2007344845871vii18061820
   PubMed Web of Science ®Google Scholar
• GoldenSHSapirTMethods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness reviewJ Manag Care Pharm201218Suppl 6S1S1722984955
   PubMedGoogle Scholar
• SelamJLEvolution of diabetes insulin delivery devicesJ Diabetes Sci Technol20104350551320513314
   PubMedGoogle Scholar
• KumareswaranKThabitHLeelarathnaLFeasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled studyDiabetes Care20143751198120324026542
   PubMed Web of Science ®Google Scholar
• BeyazitEMollaoğluMInvestigation of effect on glycosylated hemoglobin, blood pressure, and body mass index of diabetes intensive education program in patients with type 2 diabetes mellitusAm J Mens Health20115435135721406489
   PubMed Web of Science ®Google Scholar
• BlondeLMerilainenMKarweVRaskinPTITRATE Study GroupPatient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE studyDiabetes Obes Metab200911662363119515182
   PubMed Web of Science ®Google Scholar
• MeneghiniLKoenenCWengWSelamJLThe usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE 303 studyDiabetes Obes Metab20079690291317924873
   PubMed Web of Science ®Google Scholar
• CampbellRKMartinTMThe chronic burden of diabetesAm J Manag Care200915Suppl 9S248S25419817513
   PubMedGoogle Scholar
• MeneghiniLWhy and how to use insulin therapy earlier in the management of type 2 diabetesSouth Med J2007100216417417330687
   PubMed Web of Science ®Google Scholar
• American Association of Clinical EndocrinologistsAmerican College of Endocrinology consensus statement on guidelines for glycemic controlEndocr Pract20028Suppl 151111939753
   PubMedGoogle Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)Diabetes Care200326388188512610053
   PubMed Web of Science ®Google Scholar
• RiddleMUmpierrezGDiGenioAZhouRRosenstockJContributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetesDiabetes Care201134122508251422028279
   PubMed Web of Science ®Google Scholar
• PottiLGHainesSTContinuous subcutaneous insulin infusion therapy: A primer on insulin pumpsJ Am Pharm Assoc (2003)2009491e1e1319196588
   PubMed Web of Science ®Google Scholar
• EdelmanSVBodeBWBaileyTSInsulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimenDiabetes Technol Ther201012862763320615104
   PubMed Web of Science ®Google Scholar
• Labrousse-LhermineFCazalsLRuidavetsJBHanaireHGEDEC Study GroupLong-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetesDiabetes Metab200733425326017475531
   PubMed Web of Science ®Google Scholar
• ParknerTLaursenTVestergaardETInsulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetesDiabet Med200825558559118445172
   PubMed Web of Science ®Google Scholar
• SelamJLKoenenCWengWMeneghiniLImproving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 studyCurr Med Res Opin2008241112018021495
   PubMed Web of Science ®Google Scholar